{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:06:45Z","timestamp":1794456405838,"version":"4.9.1"},"publisher-location":"Totowa, NJ","reference-count":205,"publisher":"Humana Press","isbn-type":[{"value":"9781627036634","type":"print"},{"value":"9781627036641","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1007\/978-1-62703-664-1_16","type":"book-chapter","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T17:56:18Z","timestamp":1380131778000},"page":"259-309","source":"Crossref","is-referenced-by-count":31,"title":["Treatment of Infections Due to Resistant Staphylococcus aureus"],"prefix":"10.1007","author":[{"given":"Gregory M.","family":"Anstead","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Cadena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heta","family":"Javeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,30]]},"reference":[{"key":"16_CR00161","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE et al (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52:e18\u2013e55","journal-title":"Clin Infect Dis"},{"key":"16_CR00162","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.tim.2004.06.004","volume":"12","author":"JA Lindsay","year":"2004","unstructured":"Lindsay JA, Holden MTG (2004) Staphylococcus aureus: superbug, super genome? Trends Microbiol 12:378\u2013385","journal-title":"Trends Microbiol"},{"key":"16_CR00163","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1001\/jama.290.22.2976","volume":"290","author":"TS Naimi","year":"2003","unstructured":"Naimi TS, LeDell KH, Como-Sabetti K et al (2003) Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290:2976\u20132984","journal-title":"JAMA"},{"key":"16_CR00164","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1592\/phco.25.1.74.55620","volume":"25","author":"MJ Rybak","year":"2005","unstructured":"Rybak MJ, LaPlante KL (2005) Community-associated methicillin-resistant Staphylococcus aureus: a review. Pharmacotherapy 25:74\u201385","journal-title":"Pharmacotherapy"},{"key":"16_CR00165","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jhin.2009.07.004","volume":"73","author":"RL Skov","year":"2009","unstructured":"Skov RL, Jensen KS (2009) Community-associated methicillin-resistant Staphylococcus aureus as a cause of hospital-acquired infections. J Hosp Infect 73:364\u2013370","journal-title":"J Hosp Infect"},{"key":"16_CR00166","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1128\/AAC.01157-10","volume":"55","author":"ME Kraker de","year":"2011","unstructured":"de Kraker ME, Wolkewitz M, Davey PG et al (2011) Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 55:1598\u20131605","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR00167","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1001\/jama.298.15.1763","volume":"298","author":"RM Klevens","year":"2007","unstructured":"Klevens RM, Morrison MA, Nadle J (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763\u20131771","journal-title":"JAMA"},{"key":"16_CR00168","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijantimicag.2011.09.028","volume":"39","author":"IM Gould","year":"2012","unstructured":"Gould IM, David MZ, Esposito S et al (2012) New insights into methicillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents 39:96\u2013104","journal-title":"Int J Antimicrob Agents"},{"key":"16_CR00169","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1001\/jama.2010.1115","volume":"304","author":"AJ Kallen","year":"2010","unstructured":"Kallen AJ, Mu Y, Bulens S et al (2010) Health care-associated invasive MRSA infections, 2005\u20132008. JAMA 304:641\u2013648","journal-title":"JAMA"},{"key":"16_CR001610","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2012.7139","volume":"308","author":"ML Landrum","year":"2012","unstructured":"Landrum ML, Neumann C, Cook C et al (2012) Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005\u20132010. JAMA 308:50\u201359","journal-title":"JAMA"},{"issue":"Suppl 1","key":"16_CR001611","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1086\/591061","volume":"29","author":"DP Calfee","year":"2008","unstructured":"Calfee DP, Salgado CD, Classen D et al (2008) Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol 29(Suppl 1):S62\u2013S80","journal-title":"Infect Control Hosp Epidemiol"},{"key":"16_CR001612","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1086\/513203","volume":"44","author":"FC Tenover","year":"2007","unstructured":"Tenover FC, Moellering RC Jr (2007) The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 44:1208\u20131215","journal-title":"Clin Infect Dis"},{"key":"16_CR001613","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1473-3099(10)70259-0","volume":"10","author":"IM Gould","year":"2010","unstructured":"Gould IM (2010) VRSA-doomsday superbug or damp squib? Lancet Infect Dis 10:816\u2013818","journal-title":"Lancet Infect Dis"},{"key":"16_CR001614","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/cid\/cis492","volume":"55","author":"LD Saravolatz","year":"2012","unstructured":"Saravolatz LD, Pawlak J, Johnson LB (2012) In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis 55:582\u2013586","journal-title":"Clin Infect Dis"},{"key":"16_CR001615","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1086\/377501","volume":"37","author":"GK Siberry","year":"2003","unstructured":"Siberry GK, Tekle T, Carroll K, Dick J (2003) Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 37:1257\u20131260","journal-title":"Clin Infect Dis"},{"key":"16_CR001616","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1128\/JCM.41.10.4740-4744.2003","volume":"41","author":"KR Fiebelkorn","year":"2003","unstructured":"Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH (2003) Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol 41:4740\u20134744","journal-title":"J Clin Microbiol"},{"key":"16_CR001617","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/003335490912400312","volume":"124","author":"K Como-Sabetti","year":"2009","unstructured":"Como-Sabetti K, Harriman KH, Buck JM et al (2009) Community-associated methicillin-resistant Staphylococcus aureus: trends in case and isolate characteristics from six years of prospective surveillance. Public Health Rep 124:427\u2013435","journal-title":"Public Health Rep"},{"key":"16_CR001618","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1086\/491709","volume":"42","author":"DP Levine","year":"2006","unstructured":"Levine DP (2006) Vancomycin: a history. Clin Infect Dis 42:S5\u2013S12","journal-title":"Clin Infect Dis"},{"key":"16_CR001619","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.128.3.1093","volume":"128","author":"MH Kollef","year":"2005","unstructured":"Kollef MH, Micek ST (2005) Staphylococcus aureus pneumonia. A \u201csuperbug\u201d infection in community and hospital settings. Chest 128:1093\u20131096","journal-title":"Chest"},{"key":"16_CR001620","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1086\/491714","volume":"42","author":"DL Stevens","year":"2006","unstructured":"Stevens DL (2006) The role of vancomycin in the treatment paradigm. Clin Infect Dis 42:S51\u2013S57","journal-title":"Clin Infect Dis"},{"key":"16_CR001621","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1086\/510386","volume":"44","author":"ME Stryjewski","year":"2007","unstructured":"Stryjewski ME, Szczech LA, Benjamin DK Jr et al (2007) Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 44:190\u2013196","journal-title":"Clin Infect Dis"},{"key":"16_CR001622","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1164\/ajrccm.150.6.7952612","volume":"150","author":"J Rello","year":"1994","unstructured":"Rello J, Torres A, Ricart M et al (1994) Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-sensitive and methicillin-resistant episodes. Am J Respir Crit Care Med 150:1545\u20131549","journal-title":"Am J Respir Crit Care Med"},{"key":"16_CR001623","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0002-9343(03)00231-6","volume":"114","author":"AD Tice","year":"2003","unstructured":"Tice AD, Hoagland P, Shoultz DA (2003) Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 114:723\u2013728","journal-title":"Am J Med"},{"key":"16_CR001624","first-page":"583","volume-title":"The staphylococci in human disease","author":"HF Chambers","year":"1997","unstructured":"Chambers HF (1997) Parenteral antibiotics for the treatment of bacteremia and other serious staphylococcal infections. In: Crossley KB, Archer GL (eds) The staphylococci in human disease. Churchill-Livingstone, New York, pp 583\u2013601"},{"key":"16_CR001625","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ijantimicag.2010.10.029","volume":"37","author":"SP Hawser","year":"2011","unstructured":"Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T (2011) Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004\u20132009. Int J Antimicrob Agents 37:219\u2013224","journal-title":"Int J Antimicrob Agents"},{"key":"16_CR001626","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1128\/AAC.00616-09","volume":"53","author":"HS Sader","year":"2009","unstructured":"Sader HS, Fey PD, Limaye AP et al (2009) Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 53:4127\u20134132","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR001627","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/cid\/cir935","volume":"54","author":"SJ Hal van","year":"2012","unstructured":"van Hal SJ, Lodise TP, Paterson DL (2012) The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 54:755\u2013771","journal-title":"Clin Infect Dis"},{"key":"16_CR001628","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/MCC.0b013e3283578968","volume":"18","author":"A Brink","year":"2012","unstructured":"Brink A (2012) Does resistance in severe infections caused by methicillin-resistant Staphylococcus aureus give you the \u2018creeps\u2019? Curr Opin Crit Care 18:451\u2013459","journal-title":"Curr Opin Crit Care"},{"key":"16_CR001629","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC et al (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82\u201398","journal-title":"Am J Health Syst Pharm"},{"key":"16_CR001630","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jac\/dkr442","volume":"67","author":"MA Cataldo","year":"2012","unstructured":"Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N (2012) Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 67:17\u201324","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"16_CR001631","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/jac\/dks495","volume":"68","author":"SJ Vandecasteele","year":"2013","unstructured":"Vandecasteele SJ, De Vriese AS, Tacconelli E (2013) The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. J Antimicrob Chemother 68(4):743\u2013748","journal-title":"J Antimicrob Chemother"},{"key":"16_CR001632","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1128\/AAC.45.9.2460-2467.2001","volume":"45","author":"M Wysocki","year":"2001","unstructured":"Wysocki M, Delatour F, Faurisson F et al (2001) Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 45:2460\u20132467","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR001633","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1378\/chest.130.4.947","volume":"130","author":"MN Jeffres","year":"2006","unstructured":"Jeffres MN, Isakow W, Doherty JA et al (2006) Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 130:947\u2013955","journal-title":"Chest"},{"key":"16_CR001634","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.amjsurg.2009.08.045","volume":"199","author":"KM Itani","year":"2010","unstructured":"Itani KM, Dryden MS, Bhattacharyya H et al (2010) Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg 199:804\u2013816","journal-title":"Am J Surg"},{"key":"16_CR001635","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/cid\/cir078","volume":"52","author":"N Patel","year":"2011","unstructured":"Patel N, Pai MP, Rodvold KA et al (2011) Vancomycin: we can\u2019t get there from here. Clin Infect Dis 52:969\u2013974","journal-title":"Clin Infect Dis"},{"key":"16_CR001636","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","volume":"166","author":"LK Hidayat","year":"2006","unstructured":"Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A (2006) High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166:2138\u20132144","journal-title":"Arch Intern Med"},{"key":"16_CR001637","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/CE.S33430","volume":"7","author":"RR Watkins","year":"2012","unstructured":"Watkins RR, Lemonovich TL, File TM Jr (2012) An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy. Core Evid 7:131\u2013143","journal-title":"Core Evid"},{"key":"16_CR001638","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0012-3692(15)33412-7","volume":"124","author":"RG Wunderink","year":"2003","unstructured":"Wunderink RG, Bello J, Cammarata SK, Croos-Dadrera RV, Kollef MH (2003) Linezolid vs vancomycin. Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124:1789\u20131797","journal-title":"Chest"},{"key":"16_CR001639","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s00134-003-2088-1","volume":"30","author":"MH Kollef","year":"2004","unstructured":"Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG (2004) Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 30:388\u2013394","journal-title":"Intensive Care Med"},{"key":"16_CR001640","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00134-003-2135-y","volume":"30","author":"M Ioanas","year":"2004","unstructured":"Ioanas M, Lode H (2004) Linezolid in VAP by MRSA: better choice? Intensive Care Med 30:343\u2013346","journal-title":"Intensive Care Med"},{"key":"16_CR001641","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1093\/jac\/dkg262","volume":"51","author":"D Honeybourne","year":"2003","unstructured":"Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R (2003) Intrapulmonary penetration of linezolid. J Antimicrob Chemother 51:1431\u20131434","journal-title":"J Antimicrob Chemother"},{"key":"16_CR001642","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1345\/aph.1R221","volume":"46","author":"C Alaniz","year":"2012","unstructured":"Alaniz C, Pogue JM (2012) Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial. Ann Pharmacother 46:1432\u20131435","journal-title":"Ann Pharmacother"},{"key":"16_CR001643","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/cid\/cir895","volume":"54","author":"RG Wunderink","year":"2012","unstructured":"Wunderink RG, Niederman MS, Kollef MH et al (2012) Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized controlled trial. Clin Infect Dis 54:621\u2013629","journal-title":"Clin Infect Dis"},{"key":"16_CR001644","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1378\/chest.128.4.2732","volume":"128","author":"ST Micek","year":"2005","unstructured":"Micek ST, Dunne M, Kollef MH (2005) Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 128:2732\u20132738","journal-title":"Chest"},{"key":"16_CR001645","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3121\/cmr.3.2.57","volume":"3","author":"SK Shukla","year":"2005","unstructured":"Shukla SK (2005) Community-associated methicillin-resistant Staphylococcus aureus and its emerging virulence. Clin Med Res 3:57\u201360","journal-title":"Clin Med Res"},{"key":"16_CR001646","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1128\/AAC.48.2.546-555.2004","volume":"48","author":"K Bernardo","year":"2004","unstructured":"Bernardo K, Pakulat N, Fleer S et al (2004) Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 48:544\u2013546","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR001647","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1086\/426894","volume":"40","author":"JS Lewis II","year":"2005","unstructured":"Lewis JS II, Jorgensen JH (2005) Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis 40:280\u2013285","journal-title":"Clin Infect Dis"},{"key":"16_CR001648","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.amjsurg.2004.08.045","volume":"188","author":"J Weigelt","year":"2004","unstructured":"Weigelt J, Kaafarani HMA, Itani KMF, Swanson RN (2004) Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg 188:760\u2013766","journal-title":"Am J Surg"},{"key":"16_CR001649","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","volume":"49","author":"J Weigelt","year":"2005","unstructured":"Weigelt J, Itani K, Stevens D et al (2005) Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49:2260\u20132266","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR001650","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.amjsurg.2005.01.011","volume":"189","author":"JN Sharpe","year":"2005","unstructured":"Sharpe JN, Shively MD, Polk HC Jr (2005) Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 189:425\u2013428","journal-title":"Am J Surg"},{"key":"16_CR001651","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1089\/sur.2011.062","volume":"13","author":"TM Duane","year":"2012","unstructured":"Duane TM, Weigelt JA, Puzniak LA, Huang DB (2012) Linezolid and vancomycin in treatment of lower-extremity complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus in patients with and without vascular disease. Surg Infect (Larchmt) 13:147\u2013153","journal-title":"Surg Infect (Larchmt)"},{"key":"16_CR001652","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1086\/380449","volume":"38","author":"BA Lipsky","year":"2004","unstructured":"Lipsky BA, Itani K, Norden C (2004) Linezolid Diabetic Foot Infection Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam\/amoxicillin-clavulanate. Clin Infect Dis 38:17\u201324","journal-title":"Clin Infect Dis"},{"key":"16_CR001653","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s15010-004-3029-9","volume":"32","author":"CR Rayner","year":"2004","unstructured":"Rayner CR, Baddour LM, Birmingham MC et al (2004) Linezolid in the treatment of osteomyelitis: results of a compassionate use experience. Infection 32:8\u201314","journal-title":"Infection"},{"key":"16_CR001654","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ijantimicag.2006.08.030","volume":"29","author":"ME Falagas","year":"2007","unstructured":"Falagas ME, Siempos II, Papagelopoulos PJ, Vardakas KZ (2007) Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents 29:233\u2013239","journal-title":"Int J Antimicrob Agents"},{"key":"16_CR001655","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1128\/AAC.47.12.3964-3966.2003","volume":"47","author":"F Kutscha-Lissberg","year":"2003","unstructured":"Kutscha-Lissberg F, Hebler U, Muhr G, Koller M (2003) Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother 47:3964\u20133966","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR001656","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/jac\/dki355","volume":"56","author":"AF Shorr","year":"2005","unstructured":"Shorr AF, Kunkek MJ, Kollef M (2005) Linezolid versus vancomycin for Staphylococcus aureus bacteraemia; pooled analysis of randomized studies. J Antimicrob Chemother 56:923\u2013929","journal-title":"J Antimicrob Chemother"},{"key":"16_CR001657","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jinf.2012.08.007","volume":"65","author":"HJ Park","year":"2012","unstructured":"Park HJ, Kim SH, Kim MJ et al (2012) Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia. J Infect 65:505\u2013512","journal-title":"J Infect"},{"key":"16_CR001658","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1086\/595686","volume":"48","author":"MH Wilcox","year":"2009","unstructured":"Wilcox MH, Tack KJ, Bouza E et al (2009) Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 48:203\u2013212","journal-title":"Clin Infect Dis"},{"key":"16_CR001659","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1007\/s10096-012-1597-7","volume":"31","author":"TK Lauridsen","year":"2012","unstructured":"Lauridsen TK, Bruun LE, Rasmussen RV et al (2012) Linezolid as rescue treatment for left-sided infective endocarditis: an observational, retrospective, multicenter study. Eur J Clin Microbiol Infect Dis 31:2567\u20132574","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"16_CR001660","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/jac\/dkq506","volume":"66","author":"C Tascini","year":"2011","unstructured":"Tascini C, Bongiorni MG, Doria R et al (2011) Linezolid for endocarditis: a case series of 14 patients. J Antimicrob Chemother 66:679\u2013682","journal-title":"J Antimicrob Chemother"},{"key":"16_CR001661","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s15010-007-6211-z","volume":"35","author":"AT Kessler","year":"2007","unstructured":"Kessler AT, Kourtis AP (2007) Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid. Infection 35:271\u2013274","journal-title":"Infection"},{"key":"16_CR001662","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1099\/jmm.0.011130-0","volume":"58","author":"R Naesens","year":"2009","unstructured":"Naesens R, Ronsyn M, Druw\u00e9 P et al (2009) Central nervous system invasion by community-acquired meticillin-resistant Staphylococcus aureus. J Med Microbiol 58:1247\u20131251","journal-title":"J Med Microbiol"},{"key":"16_CR001663","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3109\/00365548.2011.585177","volume":"43","author":"OR Sipahi","year":"2011","unstructured":"Sipahi OR, Bardak S, Turhan T et al (2011) Linezolid in the treatment of methicillin-resistant staphylococcal post-neurosurgical meningitis: a series of 17 cases. Scand J Infect Dis 43:757\u2013764","journal-title":"Scand J Infect Dis"},{"key":"16_CR001664","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1128\/AAC.49.11.4816-4817.2005","volume":"49","author":"BP Howden","year":"2005","unstructured":"Howden BP, Charles PGP, Johnson PDR, Ward PB, Grayson ML (2005) Improved outcomes with linezolid for methicillin-resistant Staphylococcus aureus infections; better drug or reduced vancomycin susceptibility? Antimicrob Agents Chemother 49:4816\u20134817","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR001665","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1086\/524667","volume":"46","author":"A Soriano","year":"2008","unstructured":"Soriano A, Marco F, Martinez JA et al (2008) Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46:193\u2013200","journal-title":"Clin Infect Dis"},{"key":"16_CR001666","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1128\/AAC.00113-08","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Graves J, Evans A et al (2008) Relationship between vancomycin MIC and failure among patients with methicillin resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52:3315\u20133320","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR001667","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00134-011-2130-7","volume":"37","author":"EY Choi","year":"2011","unstructured":"Choi EY, Huh JW, Lim C et al (2011) Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med 37:639\u2013647","journal-title":"Intensive Care Med"},{"key":"16_CR001668","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1378\/chest.09-2453","volume":"138","author":"NZ Haque","year":"2010","unstructured":"Haque NZ, Zuniga LC, Peyrani P et al (2010) Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care associated pneumonia. Chest 138:1356\u20131362","journal-title":"Chest"},{"key":"16_CR001669","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/jac\/dki272","volume":"56","author":"B Sancak","year":"2005","unstructured":"Sancak B, Ercis S, Menemenlioglu D, \u00c7olakoglu S, Has\u00e7elik G (2005) Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 56:519\u2013523","journal-title":"J Antimicrob Chemother"},{"key":"16_CR001670","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.diagmicrobio.2012.08.010","volume":"74","author":"KM Krause","year":"2012","unstructured":"Krause KM, Blais J, Lewis SR et al (2012) In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 74:429\u2013431","journal-title":"Diagn Microbiol Infect Dis"},{"key":"16_CR001671","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1086\/518452","volume":"44","author":"S Deresinski","year":"2007","unstructured":"Deresinski S (2007) Counterpoint: vancomycin and Staphylococcus aureus\u2014an antibiotic enters obsolescence. Clin Infect Dis 44:1543\u20131548","journal-title":"Clin Infect Dis"},{"key":"16_CR001672","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1086\/381093","volume":"38","author":"PG Charles","year":"2004","unstructured":"Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML (2004) Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38:448\u2013451","journal-title":"Clin Infect Dis"},{"key":"16_CR001673","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/jac\/dkr169","volume":"66","author":"R Khatib","year":"2011","unstructured":"Khatib R, Jose J, Musta A et al (2011) Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 66:1594\u20131599","journal-title":"J Antimicrob Chemother"},{"key":"16_CR001674","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1128\/JCM.01719-10","volume":"49","author":"SW Satola","year":"2011","unstructured":"Satola SW, Lessa FC, Ray SM et al (2011) Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. aureus phenotype. J Clin Microbiol 49:1583\u20131587","journal-title":"J Clin Microbiol"},{"key":"16_CR001675","doi-asserted-by":"publisher","first-page":"e21217","DOI":"10.1371\/journal.pone.0021217","volume":"6","author":"SJ Hal van","year":"2011","unstructured":"van Hal SJ, Jones M, Gosbell IB, Paterson DL (2011) Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections. PLoS One 6:e21217","journal-title":"PLoS One"},{"key":"16_CR001676","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1086\/379327","volume":"37","author":"SA Nasraway","year":"2003","unstructured":"Nasraway SA, Shorr AF, Kuter DJ et al (2003) Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 37:1609\u20131616","journal-title":"Clin Infect Dis"},{"key":"16_CR001677","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1086\/382356","volume":"38","author":"N Rao","year":"2004","unstructured":"Rao N, Ziran BH, Wagener MM, Santa ER, Yu VL (2004) Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic devices. Clin Infect Dis 38:1058\u20131064","journal-title":"Clin Infect Dis"},{"key":"16_CR001678","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1399-3062.2011.00617.x","volume":"13","author":"S Radunz","year":"2011","unstructured":"Radunz S, Juntermanns B, Kaiser GM et al (2011) Efficacy and safety of linezolid in liver transplant patients. Transpl Infect Dis 13:353\u2013358","journal-title":"Transpl Infect Dis"},{"key":"16_CR001679","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1086\/500139","volume":"42","author":"B Jaksic","year":"2006","unstructured":"Jaksic B, Martinelli G, Perez-Oteyza J et al (2006) Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 42:597\u2013607","journal-title":"Clin Infect Dis"},{"key":"16_CR001680","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1345\/aph.1E523","volume":"39","author":"L Bergeron","year":"2005","unstructured":"Bergeron L, Boul\u00e9 M, Perreault S (2005) Serotonin toxicity associated with concomitant use of linezolid. Ann Pharmacother 39:956\u2013961","journal-title":"Ann Pharmacother"},{"key":"16_CR001681","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/jac\/dkr467","volume":"67","author":"JM Butterfield","year":"2012","unstructured":"Butterfield JM, Lawrence KR, Reisman A et al (2012) Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of phase III and IV randomized clinical trial data. J Antimicrob Chemother 67:494\u2013502","journal-title":"J Antimicrob Chemother"},{"key":"16_CR001682","unstructured":"Anonymous (2004) Pfizer: Zyvox (linezolid). Safety-nervous-psychiatric. Reports of peripheral or optic neuropathy. Data on file"},{"key":"16_CR001683","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1086\/345744","volume":"36","author":"MC Birmingham","year":"2003","unstructured":"Birmingham MC, Rayner CR, Meagher AK et al (2003) Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36:159\u2013168","journal-title":"Clin Infect Dis"},{"key":"16_CR001684","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/jac\/dkh199","volume":"53","author":"F Frippiat","year":"2004","unstructured":"Frippiat F, Bergiers C, Michel C, Dujardin JP, Derue G (2004) Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Chemother 53:114\u2013115","journal-title":"J Antimicrob Chemother"},{"key":"16_CR001685","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s15010-005-4057-9","volume":"33","author":"T Ferry","year":"2005","unstructured":"Ferry T, Ponceau B, Simon M et al (2005) Possibly linezolid-induced peripheral and central nervous system neurotoxicity: report of four cases. Infection 33:151\u2013154","journal-title":"Infection"},{"key":"16_CR001686","unstructured":"US Food and Drug Administration (2013) Highlights of prescribing information-Zyvox. \n                  www.accessdata.fda.gov\/drugsatfdadocs\/-label\/2008\/021130s016,021131s013,021132s014lbl.pdf\n                  \n                . Accessed 25 Jan 2013"},{"key":"16_CR001687","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1345\/aph.1D032","volume":"37","author":"BM Lomaestro","year":"2003","unstructured":"Lomaestro BM (2003) Resistance to linezolid. Are we surprised? How hard should we look? Ann Pharmacother 37:909\u2013911","journal-title":"Ann Pharmacother"},{"key":"16_CR001688","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.diagmicrobio.2011.09.023","volume":"72","author":"RE Mendes","year":"2012","unstructured":"Mendes RE, Sader HS, Farrell DJ, Jones RN (2012) Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA hospitals (2007\u20132009). Diagn Microbiol Infect Dis 72:113\u2013117","journal-title":"Diagn Microbiol Infect Dis"},{"key":"16_CR001689","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1086\/650574","volume":"50","author":"G Morales","year":"2010","unstructured":"Morales G, Picazo JJ, Baos E et al (2010) Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 50:821\u2013825","journal-title":"Clin Infect Dis"},{"key":"16_CR001690","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1128\/AAC.00177-10","volume":"54","author":"F Pea","year":"2010","unstructured":"Pea F, Furlanut M, Cojutti P et al (2010) Therapeutic drug monitoring of linezolid: a retrospective, monocentric analysis. Antimicrob Agents Chemother 54:4605\u20134610","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR001691","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2165\/00003495-200464040-00009","volume":"64","author":"C Fenton","year":"2004","unstructured":"Fenton C, Keating GM, Curran MP (2004) Daptomycin. Drugs 64:445\u2013455","journal-title":"Drugs"},{"key":"16_CR001692","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1086\/420818","volume":"38","author":"RD Arbeit","year":"2004","unstructured":"Arbeit RD, Maki D, Tally FP et al (2004) The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38:1673\u20131681","journal-title":"Clin Infect Dis"},{"key":"16_CR001693","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa053783","volume":"355","author":"VG Fowler Jr","year":"2006","unstructured":"Fowler VG Jr, Boucher HW, Corey GR et al (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653\u2013665","journal-title":"N Engl J Med"},{"key":"16_CR001694","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/cid\/cir764","volume":"54","author":"CL Moore","year":"2012","unstructured":"Moore CL, Osaki-Kiyan P, Haque NZ et al (2012) Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 54:51\u201358","journal-title":"Clin Infect Dis"},{"key":"16_CR001695","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.clinthera.2011.09.007","volume":"33","author":"S Jobson","year":"2011","unstructured":"Jobson S, Moise PA, Eskandarian R (2011) Retrospective observational study comparing vancomycin versus daptomycin as initial therapy for Staphylococcus aureus infections. Clin Ther 33:1391\u20131399","journal-title":"Clin Ther"},{"key":"16_CR001696","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.clinthera.2012.06.013","volume":"34","author":"RP Moenster","year":"2012","unstructured":"Moenster RP, Linneman TW, Finnegan PM, McDonald JR (2012) Daptomycin compared to vancomycin for the treatment of osteomyelitis: a single-center, retrospective cohort study. Clin Ther 34:1521\u20131527","journal-title":"Clin Ther"},{"key":"16_CR001697","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/1471-2334-12-133","volume":"12","author":"JC Gallagher","year":"2012","unstructured":"Gallagher JC, Huntington JA, Culshaw D et al (2012) Daptomycin therapy for osteomyelitis: a retrospective study. BMC Infect Dis 12:133","journal-title":"BMC Infect Dis"},{"key":"16_CR001698","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.1128\/AAC.00455-10","volume":"54","author":"J Parra-Ruiz","year":"2010","unstructured":"Parra-Ruiz J, Vidaillac C, Rose WE et al (2010) Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob Agents Chemother 54:4329\u20134334","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR001699","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jac\/dki058","volume":"55","author":"K Echevarria","year":"2005","unstructured":"Echevarria K, Datta P, Cadena J, Lewis JS II (2005) Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 55:599\u2013600","journal-title":"J Antimicrob Chemother"},{"key":"16_CR0016100","first-page":"1","volume":"9","author":"LK Golightly","year":"2013","unstructured":"Golightly LK, Barber GR, Barron MA, Page RL II (2013) Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability. Drug Metabol Drug Interact 9:1\u201310","journal-title":"Drug Metabol Drug Interact"},{"key":"16_CR0016101","first-page":"115","volume":"4","author":"B White","year":"2011","unstructured":"White B, Seaton RA (2011) Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin. Infect Drug Resist 4:115\u2013127","journal-title":"Infect Drug Resist"},{"key":"16_CR0016102","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/cid\/cir805","volume":"54","author":"E Durante-Mangoni","year":"2012","unstructured":"Durante-Mangoni E, Casillo R, Bernardo M et al (2012) High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis. Clin Infect Dis 54:347\u2013354","journal-title":"Clin Infect Dis"},{"key":"16_CR0016103","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1592\/phco.31.6.527","volume":"31","author":"R Kullar","year":"2011","unstructured":"Kullar R, Davis SL, Levine DP et al (2011) High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 31:527\u2013536","journal-title":"Pharmacotherapy"},{"key":"16_CR0016104","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1128\/AAC.47.5.1714-1718.2003","volume":"47","author":"G Sakoulas","year":"2003","unstructured":"Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT (2003) Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 47:1714\u20131718","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016105","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1128\/AAC.49.7.2735-2745.2005","volume":"49","author":"BT Tsuji","year":"2005","unstructured":"Tsuji BT, Rybak MJ (2005) Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 49:2735\u20132745","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016106","doi-asserted-by":"publisher","first-page":"5709","DOI":"10.1128\/AAC.01185-12","volume":"56","author":"ME Steed","year":"2012","unstructured":"Steed ME, Werth BJ, Ireland CE, Rybak MJ (2012) Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic\/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother 56:5709\u20135714","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016107","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.1128\/AAC.01525-12","volume":"56","author":"S Mehta","year":"2012","unstructured":"Mehta S, Singh C, Plata KB et al (2012) \u03b2-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 56:6192\u20136200","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016108","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1128\/AAC.00797-12","volume":"56","author":"WE Rose","year":"2012","unstructured":"Rose WE, Schulz LT, Andes D et al (2012) Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 56:5296\u20135302","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016109","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/cid\/cir340","volume":"53","author":"A Dhand","year":"2011","unstructured":"Dhand A, Bayer AS, Pogliano J et al (2011) Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 53:158\u2013163","journal-title":"Clin Infect Dis"},{"key":"16_CR0016110","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/jac\/dkp346","volume":"64","author":"JN Steenbergen","year":"2009","unstructured":"Steenbergen JN, Mohr JF, Thorne GM (2009) Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J Antimicrob Chemother 64:1130\u20131138","journal-title":"J Antimicrob Chemother"},{"key":"16_CR0016111","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10096-010-1128-3","volume":"30","author":"SJ Hal van","year":"2011","unstructured":"van Hal SJ, Paterson DL, Gosbell IB (2011) Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-na\u00efve patient\u2014a review of the literature. Eur J Clin Microbiol Infect Dis 30:603\u2013610","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"16_CR0016112","first-page":"3169","volume":"54","author":"SJ Yang","year":"2010","unstructured":"Yang SJ, Xiong YQ, Boyle-Vavra S et al (2010) Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the \u201cseesaw effect\u201d). Antimicrob Agents Chemother 54:3169\u20133179","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016113","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0305-7372(03)00069-0","volume":"29","author":"J Klastersky","year":"2003","unstructured":"Klastersky J (2003) Role of quinupristin\/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients. Cancer Treat Rev 29:431\u2013440","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"16_CR0016114","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10096-013-1824-x","volume":"32","author":"B Guignard","year":"2013","unstructured":"Guignard B, Vouillamoz J, Giddey M, Moreillon P (2013) A positive interaction between inhibitors of protein synthesis and cefepime in the fight against methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 32(7):899\u2013907","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"16_CR0016115","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/0022-3859.48443","volume":"55","author":"M Bhattacharya","year":"2009","unstructured":"Bhattacharya M, Parakh A, Narang MJ (2009) Tigecycline. Postgrad Med 55:65\u201368","journal-title":"Postgrad Med"},{"key":"16_CR0016116","unstructured":"European Medicines Agency (EMA) (2011) Questions and answers on the review of Tygacil (tigecycline). Outcome of a renewal procedure EMA, London, UK. [EMA\/121925\/2011] \n                  http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Medicine_QA\/human\/000644\/WC500102228.pdf\n                  \n                . Accessed 21 Jul 2011"},{"key":"16_CR0016117","unstructured":"Pfizer (2011) Direct healthcare professional communication on increase in mortality in clinical trials of Tygacil\u00ae (tigecycline)"},{"key":"16_CR0016118","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1128\/AAC.01402-10","volume":"55","author":"Y Cai","year":"2011","unstructured":"Cai Y, Wang R, Liang B, Bai N, Liu Y (2011) Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious diseases. Antimicrob Agents Chemother 55:1162\u20131172","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016119","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.diagmicrobio.2008.10.011","volume":"63","author":"PG Ambrose","year":"2009","unstructured":"Ambrose PG, Meagher AK, Passarell JA et al (2009) Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagn Microbiol Infect Dis 63:155\u2013159","journal-title":"Diagn Microbiol Infect Dis"},{"key":"16_CR0016120","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.diagmicrobio.2012.01.015","volume":"73","author":"YP Chong","year":"2012","unstructured":"Chong YP, Park SJ, Kim HS et al (2012) In vitro activities of ceftobiprole, dalbavancin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus blood isolates: stratified analysis by vancomycin MIC. Diagn Microbiol Infect Dis 73:264\u2013266","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 5","key":"16_CR0016121","doi-asserted-by":"publisher","first-page":"S333","DOI":"10.1086\/431674","volume":"41","author":"AK Meagher","year":"2005","unstructured":"Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ (2005) The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 41(Suppl 5):S333\u2013S340","journal-title":"Clin Infect Dis"},{"key":"16_CR0016122","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0149-2918(11)00020-8","volume":"32","author":"MH Chang","year":"2010","unstructured":"Chang MH, Kish TD, Fung HB (2010) Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults. Clin Ther 32:2160\u20132185","journal-title":"Clin Ther"},{"key":"16_CR0016123","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1086\/587896","volume":"46","author":"ME Stryjewski","year":"2008","unstructured":"Stryjewski ME, Graham DR, Wilson SE et al (2008) Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 46:1683\u20131693","journal-title":"Clin Infect Dis"},{"key":"16_CR0016124","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1586\/eri.12.81","volume":"10","author":"EC Nannini","year":"2012","unstructured":"Nannini EC, Corey GR, Stryjewski ME (2012) Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies. Expert Rev Anti Infect Ther 10:847\u2013854","journal-title":"Expert Rev Anti Infect Ther"},{"key":"16_CR0016125","doi-asserted-by":"publisher","first-page":"e41870","DOI":"10.1371\/journal.pone.0041870","volume":"7","author":"KA Polyzos","year":"2012","unstructured":"Polyzos KA, Mavros MN, Vardakas KZ et al (2012) Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS One 7:e41870","journal-title":"PLoS One"},{"key":"16_CR0016126","unstructured":"Theravance Inc. (2011) Important update regarding the availability of VIBATIV\u00ae (telavancin for injection). \n                  http:\/\/files.shareholder.com\/downloads\/THERA\/0x0xS1104659-1164687\/1080014\/filing.pdf\n                  \n                . Accessed 2 Jan 2013."},{"issue":"Suppl 3","key":"16_CR0016127","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1093\/cid\/cis559","volume":"55","author":"TM File Jr","year":"2012","unstructured":"File TM Jr, Wilcox MH, Stein GE (2012) Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 55(Suppl 3):S173\u2013S180","journal-title":"Clin Infect Dis"},{"key":"16_CR0016128","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1128\/AAC.00347-11","volume":"55","author":"M Steed","year":"2011","unstructured":"Steed M, Vidaillac C, Rybak MJ (2011) Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-non-susceptible methicillinresistant Staphylococcus aureus strains in an in vitro pharmacokinetic\/pharmacodynamic model. Antimicrob Agents Chemother 55:3522\u20133526","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jac\/dkq255","volume":"65","author":"MH Wilcox","year":"2010","unstructured":"Wilcox MH, Corey GR, Talbot GH (2010) CANVAS 2: the second phase III, randomized double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65:53\u201365","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 4","key":"16_CR0016130","first-page":"S41","volume":"65","author":"GR Corey","year":"2010","unstructured":"Corey GR, Wilcox MH, Talbot GH (2010) CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65(Suppl 4):S41\u2013S51","journal-title":"J Antimicrob Chemother"},{"key":"16_CR0016131","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/jac\/dks006","volume":"67","author":"TT Ho","year":"2012","unstructured":"Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS II (2012) Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 67:1267\u20131270","journal-title":"J Antimicrob Chemother"},{"key":"16_CR0016132","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2165\/00003495-200969070-00003","volume":"69","author":"GG Zhanel","year":"2009","unstructured":"Zhanel GG, Sniezek G, Schweizer F et al (2009) Ceftaroline: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Drugs 69:809\u2013831","journal-title":"Drugs"},{"key":"16_CR0016133","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1128\/AAC.00984-09","volume":"53","author":"C Jacqueline","year":"2009","unstructured":"Jacqueline C, Caillon J, Le Mabecque V et al (2009) In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin. Antimicrob Agents Chemother 53:5300\u20135302","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016134","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1128\/AAC.01242-06","volume":"51","author":"C Jacqueline","year":"2007","unstructured":"Jacqueline C, Caillon J, Le Mabecque V et al (2007) In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 51:3397\u20133400","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016135","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1093\/jac\/dkq193","volume":"65","author":"C Jacqueline","year":"2010","unstructured":"Jacqueline C, Amador G, Caillon J et al (2010) Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother 65:1749\u20131752","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"16_CR0016136","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s10156-012-0449-9","volume":"19","author":"JC Lin","year":"2013","unstructured":"Lin JC, Aung G, Thomas A et al (2013) The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother 19(1):42\u201349","journal-title":"J Infect Chemother"},{"key":"16_CR0016137","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1016\/S0149-2918(03)90101-9","volume":"25","author":"M McCollum","year":"2003","unstructured":"McCollum M, Rhew DC, Parodi S (2003) Cost analysis of switching from IV vancomycin to po linezolid for the management of methicillin-resistant Staphylococcus species. Clin Ther 25:3173\u20133189","journal-title":"Clin Ther"},{"key":"16_CR0016138","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ijantimicag.2005.09.003","volume":"26","author":"KMF Itani","year":"2005","unstructured":"Itani KMF, Weigelt J, Li JZ, Duttagupta S (2005) Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 26:442\u2013448","journal-title":"Int J Antimicrob Agents"},{"key":"16_CR0016139","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1007\/s10096-012-1603-0","volume":"31","author":"I Vesteinsdottir","year":"2012","unstructured":"Vesteinsdottir I, Gudlaugsdottir S, Einarsdottir R et al (2012) Risk factors for Clostridium difficile toxin-positive diarrhea: a population-based prospective case-control study. Eur J Clin Microbiol Infect Dis 31:2601\u20132610","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"16_CR0016140","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/clinids\/13.5.1023","volume":"13","author":"JH Yuk","year":"1991","unstructured":"Yuk JH, Dignani MC, Harris RL, Bradshaw MW, Williams TW Jr (1991) Minocycline as an alternative antistaphylococcal agent. Rev Infect Dis 13:1023\u20131024","journal-title":"Rev Infect Dis"},{"key":"16_CR0016141","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1128\/AAC.00262-07","volume":"51","author":"JJ Ruhe","year":"2007","unstructured":"Ruhe JJ, Menon A (2007) Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 51:3298\u20133303","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016142","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1128\/AAC.38.7.1515","volume":"38","author":"DP Nicolau","year":"1994","unstructured":"Nicolau DP, Freeman CD, Nightingale CH, Coe CJ, Quintiliani R (1994) Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 38:1515\u20131518","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016143","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ijantimicag.2010.01.017","volume":"35","author":"BA Cunha","year":"2010","unstructured":"Cunha BA (2010) Minocycline versus doxycycline for meticillin-resistant Staphylococcus aureus (MRSA): in vitro susceptibility versus in vivo effectiveness. Int J Antimicrob Agents 35:517\u2013518","journal-title":"Int J Antimicrob Agents"},{"key":"16_CR0016144","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1128\/AAC.49.12.5024-5032.2005","volume":"49","author":"DC Draghi","year":"2005","unstructured":"Draghi DC, Sheehan DJ, Hogan P, Sahm DF (2005) In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 Surveillance Program. Antimicrob Agents Chemother 49:5024\u20135032","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1197\/j.aem.2006.08.008","volume":"14","author":"MB Hasty","year":"2007","unstructured":"Hasty MB, Klasner A, Kness S (2007) Cutaneous community-associated methicillin-resistant Staphylococcus aureus among all skin and soft-tissue infections in two geographically distant pediatric emergency departments. Acad Emerg Med 14:35\u201340","journal-title":"Acad Emerg Med"},{"key":"16_CR0016146","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1056\/NEJMoa055356","volume":"355","author":"GJ Moran","year":"2006","unstructured":"Moran GJ, Krishnadasan A, Gorwitz RJ et al (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355:666\u2013674","journal-title":"N Engl J Med"},{"key":"16_CR0016147","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/archinte.168.8.805","volume":"168","author":"J Perlroth","year":"2008","unstructured":"Perlroth J, Kuo M, Tan J, Bayer AS, Miller LG (2008) Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 168:805\u2013819","journal-title":"Arch Intern Med"},{"key":"16_CR0016148","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1128\/AAC.47.8.2655-2658.2003","volume":"47","author":"CF Dailey","year":"2003","unstructured":"Dailey CF, Pagano PJ, Buchanan LV et al (2003) Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 47:2655\u20132658","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016149","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1128\/AAC.00051-09","volume":"53","author":"JM Mir\u00f3","year":"2009","unstructured":"Mir\u00f3 JM, Garc\u00eda-de-la-M\u00e0ria C, Armero Y et al (2009) Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53:4172\u20134177","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016150","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.clpt.2005.01.020","volume":"77","author":"H Egle","year":"2005","unstructured":"Egle H, Trittler R, Kummerer K, Lemmen SW (2005) Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther 77:451\u2013453","journal-title":"Clin Pharmacol Ther"},{"key":"16_CR0016151","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/CCM.0b013e3181b9ecea","volume":"38","author":"YJ Jung","year":"2010","unstructured":"Jung YJ, Koh Y, Hong SB et al (2010) Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 38:175\u2013180","journal-title":"Crit Care Med"},{"key":"16_CR0016152","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/CCM.0b013e3181c0dc8f","volume":"38","author":"KM Ramsey","year":"2010","unstructured":"Ramsey KM, Mazer MA (2010) Addition of rifampin to vancomycin for the treatment of pneumonias due to methicillin-resistant Staphylococcus aureus: caveat emptor. Crit Care Med 38:326\u2013327","journal-title":"Crit Care Med"},{"key":"16_CR0016153","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ijantimicag.2010.07.008","volume":"36","author":"M Lefebvre","year":"2010","unstructured":"Lefebvre M, Jacqueline C, Amador G et al (2010) Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis. Int J Antimicrob Agents 36:542\u2013544","journal-title":"Int J Antimicrob Agents"},{"key":"16_CR0016154","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/j.1469-0691.2009.02761.x","volume":"15","author":"S Nguyen","year":"2009","unstructured":"Nguyen S, Pasquet A, Legout L et al (2009) Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect 15:1163\u20131169","journal-title":"Clin Microbiol Infect"},{"key":"16_CR0016155","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jinf.2006.11.011","volume":"54","author":"NG Daver","year":"2007","unstructured":"Daver NG, Shelburne SA, Atmar RL et al (2007) Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect 54:539\u2013544","journal-title":"J Infect"},{"key":"16_CR0016156","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1128\/AAC.00226-10","volume":"54","author":"C Garrig\u00f3s","year":"2010","unstructured":"Garrig\u00f3s C, Murillo O, Euba G et al (2010) Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 54:5251\u20135256","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016157","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1128\/AAC.00047-09","volume":"53","author":"AK John","year":"2009","unstructured":"John AK, Baldoni D, Haschke M et al (2009) Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother 53:2719\u20132724","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016158","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1128\/AAC.01570-12","volume":"57","author":"C Garrig\u00f3s","year":"2013","unstructured":"Garrig\u00f3s C, Murillo O, Lora-Tamayo J et al (2013) Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 57:606\u2013610","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016159","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1574-695X.2012.00938.x","volume":"65","author":"W Zimmerli","year":"2012","unstructured":"Zimmerli W, Moser C (2012) Pathogenesis and treatment concepts of orthopaedic biofilm infections. FEMS Immunol Med Microbiol 65:158\u2013168","journal-title":"FEMS Immunol Med Microbiol"},{"key":"16_CR0016160","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","volume":"279","author":"W Zimmerli","year":"1998","unstructured":"Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE (1998) Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 279:1537\u20131541","journal-title":"JAMA"},{"key":"16_CR0016161","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijantimicag.2004.03.009","volume":"24","author":"B Shopsin","year":"2004","unstructured":"Shopsin B, Zhao X, Kreiswirth BN, Tillotson GS, Drlica K (2004) Are the new quinolones appropriate treatment for community-acquired methicillin-resistant Staphylococcus aureus? Internat J Antimicrob Agents 24:32\u201334","journal-title":"Internat J Antimicrob Agents"},{"key":"16_CR0016162","doi-asserted-by":"publisher","first-page":"5161","DOI":"10.1128\/AAC.00027-10","volume":"54","author":"JR San","year":"2010","unstructured":"San JR, Garcia-Reyne A, Caba P et al (2010) Safety and efficacy of moxifloxacin monotherapy for treatment of treatment of orthopedic implant-related staphylococcal infections. Antimicrob Agents Chemother 54:5161\u20135166","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016163","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/1471-2334-12-286","volume":"12","author":"A Shittu","year":"2102","unstructured":"Shittu A, Oyedara O, Abegunrin F et al (2102) Characterization of methicillin-susceptible and -resistant staphylococci in the clinical setting: a multicentre study in Nigeria. BMC Infect Dis 12:286","journal-title":"BMC Infect Dis"},{"key":"16_CR0016164","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/01.qco.0000186850.54040.fc","volume":"18","author":"MW Ellis","year":"2005","unstructured":"Ellis MW, Lewis JS II (2005) Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus. Curr Opin Infect Dis 18:496\u2013501","journal-title":"Curr Opin Infect Dis"},{"key":"16_CR0016165","doi-asserted-by":"publisher","first-page":"390","DOI":"10.7326\/0003-4819-117-5-390","volume":"117","author":"N Markowitz","year":"1992","unstructured":"Markowitz N, Quinn EL, Saravolatz LD (1992) Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment for the treatment of Staphylococcus aureus infection. Ann Intern Med 117:390\u2013398","journal-title":"Ann Intern Med"},{"key":"16_CR0016166","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1128\/AAC.39.4.953","volume":"39","author":"M G\u00f3rgolas de","year":"1995","unstructured":"de G\u00f3rgolas M, Avil\u00e9s P, Vedejo C, Fernandez Guerrero ML (1995) Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob Agents Chemother 39:953\u2013957","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016167","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1128\/AAC.00706-11","volume":"55","author":"J Cadena","year":"2011","unstructured":"Cadena J, Nair S, Henao-Martinez AF et al (2011) Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 55:5430\u20135432","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016168","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3122\/jabfm.2010.06.090270","volume":"23","author":"CR Frei","year":"2010","unstructured":"Frei CR, Miller ML, Lewis JS II et al (2010) Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections. J Am Board Fam Med 23:714\u2013719","journal-title":"J Am Board Fam Med"},{"key":"16_CR0016169","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1345\/aph.1R211","volume":"46","author":"ML Campbell","year":"2012","unstructured":"Campbell ML, Marchaim D, Pogue JM et al (2012) Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 \u03bcg\/mL to vancomycin: old (trimethoprim\/sulfamethoxazole) versus new (daptomycin or linezolid) agents. Ann Pharmacother 46:1587\u20131597","journal-title":"Ann Pharmacother"},{"key":"16_CR0016170","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/AAC.42.12.3086","volume":"42","author":"A Stein","year":"1998","unstructured":"Stein A, Bataille JF, Drancourt M et al (1998) Ambulatory treatment of multi-drug resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 42:3086\u20133091","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016171","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1086\/345758","volume":"36","author":"JR Johnson","year":"2003","unstructured":"Johnson JR (2003) Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 36:236\u2013237","journal-title":"Clin Infect Dis"},{"key":"16_CR0016172","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2003.12.043","volume":"50","author":"S Iyer","year":"2004","unstructured":"Iyer S, Jones DH (2004) Community-acquired methicillin-resistant skin infections: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 50:854\u2013858","journal-title":"J Am Acad Dermatol"},{"key":"16_CR0016173","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1086\/499365","volume":"42","author":"BP Howden","year":"2006","unstructured":"Howden BP, Grayson ML (2006) Dumb and dumber\u2014the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 42:394\u2013400","journal-title":"Clin Infect Dis"},{"key":"16_CR0016174","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijantimicag.2012.03.010","volume":"40","author":"JL Wang","year":"2012","unstructured":"Wang JL, Tang HJ, Hsieh PH et al (2012) Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 40:103\u2013107","journal-title":"Int J Antimicrob Agents"},{"key":"16_CR0016175","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/1471-2334-10-351","volume":"10","author":"GD Katopodis","year":"2010","unstructured":"Katopodis GD, Grivea IN, Tsantsaridou AJ et al (2010) Fusidic acid and clindamycin resistance in community-associated, methicillin-resistant Staphylococcus aureus infections in children of Central Greece. BMC Infect Dis 10:351","journal-title":"BMC Infect Dis"},{"key":"16_CR0016176","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ijantimicag.2009.10.023","volume":"35","author":"MA Pfaller","year":"2010","unstructured":"Pfaller MA, Castanheira M, Sader HS, Jones RN (2010) Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada. Int J Antimicrob Agents 35:282\u2013287","journal-title":"Int J Antimicrob Agents"},{"key":"16_CR0016177","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1128\/AAC.02061-12","volume":"57","author":"TN Peel","year":"2013","unstructured":"Peel TN, Buising KL, Dowsey MM et al (2013) Outcome of debridement and retention in prosthetic joint infections by methicillin-resistant staphylococci, with special reference to rifampin and fusidic acid combination therapy. Antimicrob Agents Chemother 57:350\u2013355","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 7","key":"16_CR0016178","doi-asserted-by":"publisher","first-page":"S542","DOI":"10.1093\/cid\/cir170","volume":"52","author":"P Fernandes","year":"2011","unstructured":"Fernandes P, Pereira D (2011) Efforts to support the development of fusidic acid in the United States. Clin Infect Dis 52(Suppl 7):S542\u2013S546","journal-title":"Clin Infect Dis"},{"issue":"Suppl 7","key":"16_CR0016179","doi-asserted-by":"publisher","first-page":"S520","DOI":"10.1093\/cid\/cir167","volume":"52","author":"JC Craft","year":"2011","unstructured":"Craft JC, Moriarty SR, Clark K et al (2011) A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin Infect Dis 52(Suppl 7):S520\u2013S526","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"16_CR0016180","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1111\/j.1444-0903.2005.00976.x","volume":"35","author":"C Rayner","year":"2005","unstructured":"Rayner C, Munckhof WJ (2005) Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus. Intern Med J 35(Suppl 2):S3\u2013S16","journal-title":"Intern Med J"},{"key":"16_CR0016181","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s10096-011-1441-5","volume":"31","author":"B Lamy","year":"2012","unstructured":"Lamy B, Laurent F, Gallon O et al (2012) Antibacterial resistance, genes encoding toxins and genetic background among Staphylococcus aureus isolated from community-acquired skin and soft tissue infections in France: a national prospective survey. Eur J Clin Microbiol Infect Dis 31:1279\u20131284","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"16_CR0016182","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/jac\/48.2.209","volume":"48","author":"K Grif","year":"2001","unstructured":"Grif K, Dierich MP, Pfaller K, Miglioli PA, Allerberger F (2001) In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 48:209\u2013217","journal-title":"J Antimicrob Chemother"},{"key":"16_CR0016183","first-page":"95","volume":"71","author":"JM Hamilton-Miller","year":"1992","unstructured":"Hamilton-Miller JM (1992) In vitro activity of fosfomycin against \u2018problem\u2019 gram-positive cocci. Microbios 71:95\u2013103","journal-title":"Microbios"},{"key":"16_CR0016184","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1128\/AAC.00881-10","volume":"55","author":"W Poeppl","year":"2011","unstructured":"Poeppl W, Tobudic S, Lingscheid T et al (2011) Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 55:931\u2013933","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016185","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/jac\/dkp230","volume":"64","author":"MV Schintler","year":"2009","unstructured":"Schintler MV, Traunm\u00fcller F, Metzler J et al (2009) High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother 64:574\u2013578","journal-title":"J Antimicrob Chemother"},{"key":"16_CR0016186","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jcf.2011.09.006","volume":"11","author":"G McCaughey","year":"2012","unstructured":"McCaughey G, McKevitt M, Elborn JS, Tunney MM (2012) Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. J Cyst Fibros 11:63\u201372","journal-title":"J Cyst Fibros"},{"key":"16_CR0016187","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/01.inf.0000109288.06912.21","volume":"23","author":"MC Lee","year":"2004","unstructured":"Lee MC, Rios AM, Aten MF et al (2004) Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 23:123\u2013127","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl 3","key":"16_CR0016188","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1093\/cid\/cir920","volume":"54","author":"GG Zhanel","year":"2012","unstructured":"Zhanel GG, Schweizer F, Karlowsky JA (2012) Oritavancin: mechanism of action. Clin Infect Dis 54(Suppl 3):S214\u2013S219","journal-title":"Clin Infect Dis"},{"key":"16_CR0016189","unstructured":"Giamarellou H, O\u2019Riordan W, Harris H et al (2003) Phase 3 trial comparing 3\u20137 days of oritavancin vs. 10\u201314 days of vancomycin\/cephalexin in the treatment of patients with complicated skin and skin structure infections (cSSSI) [abstract L-739a]. In: Program and abstracts of the 43rd interscience conference of antimicrobial agents and chemotherapy (Chicago, IL). American Society for Microbiology, Washington, DC"},{"key":"16_CR0016190","unstructured":"Wasilewski M, Disch D, McGill J et al (2001) Equivalence of shorter course therapy with oritavancin vs. vancomycin\/cephalexin in complicated skin-skin structure infections (cSSSI) [abstract UL-18]. In: Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy (Chicago, IL). American Society for Microbiology, Washington, DC"},{"issue":"Suppl 3","key":"16_CR0016191","doi-asserted-by":"publisher","first-page":"S233","DOI":"10.1093\/cid\/cir924","volume":"54","author":"CA Arias","year":"2012","unstructured":"Arias CA, Mendes RE, Stilwell MG, Jones RN, Murray BE (2012) Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections. Clin Infect Dis 54(Suppl 3):S233\u2013S238","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"16_CR0016192","first-page":"S122","volume":"10","author":"JS Loutit","year":"2004","unstructured":"Loutit JS, O\u2019Riordan W, San Juan J et al (2004) Phase 2 trial comparing four regimens of oritavancin vs. comparator in the treatment of patients with S. aureus bacteremia. Clin Microbiol Infect 10(Suppl 3):S122","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 3","key":"16_CR0016193","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.1093\/cid\/cir1047","volume":"54","author":"A Tice","year":"2012","unstructured":"Tice A (2012) Oritavancin: a new opportunity for outpatient therapy of serious infections. Clin Infect Dis 54(Suppl 3):S239\u2013S243","journal-title":"Clin Infect Dis"},{"key":"16_CR0016194","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1128\/AAC.00029-11","volume":"55","author":"LM Dunbar","year":"2011","unstructured":"Dunbar LM, Milata J, McClure T, Wasilewski MM, SIMPLIFI Study Team (2011) Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother 55:3476\u20133484","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016195","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","volume":"70","author":"GG Zhanel","year":"2010","unstructured":"Zhanel GG, Calic D, Schweizer F et al (2010) New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70:859\u2013886","journal-title":"Drugs"},{"key":"16_CR0016196","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1086\/497271","volume":"41","author":"LE Jauregui","year":"2005","unstructured":"Jauregui LE, Babazadeh S, Seltzer E et al (2005) Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 41:1407\u20131415","journal-title":"Clin Infect Dis"},{"issue":"2","key":"16_CR0016197","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4161\/viru.22507","volume":"4","author":"IM Gould","year":"2013","unstructured":"Gould IM, Bal AM (2013) New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence 4(2):185\u2013191","journal-title":"Virulence"},{"key":"16_CR0016198","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1128\/AAC.00458-12","volume":"56","author":"PP Prokocimer","year":"2012","unstructured":"Prokocimer PP, Bien P, Deanda C, Pillar CM, Bartizal K (2012) In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 56:4608\u20134613","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016199","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1128\/AAC.01724-09","volume":"54","author":"S Lemaire","year":"2010","unstructured":"Lemaire S, Kosowska-Shick K, Appelbaum PC et al (2010) Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob Agents Chemother 54:2549\u20132559","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016200","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1128\/AAC.01201-10","volume":"55","author":"S Lemaire","year":"2011","unstructured":"Lemaire S, Tulkens PM, Van Bambeke F (2011) Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother 55:649\u2013658","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016201","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1128\/AAC.05044-11","volume":"55","author":"P Covington","year":"2011","unstructured":"Covington P, Davenport JM, Andrae D et al (2011) Randomized, double-blind, phase II, multicenter study evaluating the safety\/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection. Antimicrob Agents Chemother 55:5790\u20135797","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016202","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1128\/AAC.00948-12","volume":"56","author":"GJ Noel","year":"2012","unstructured":"Noel GJ, Draper MP, Hait H, Tanaka SK, Arbeit RD (2012) A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 56:5650\u20135654","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016203","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ijantimicag.2011.04.023","volume":"38","author":"C Vidaillac","year":"2011","unstructured":"Vidaillac C, Parra-Ruiz J, Winterfield P, Rybak MJ (2011) In vitro pharmacokinetic\/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates. Int J Antimicrob Agents 38:301\u2013306","journal-title":"Int J Antimicrob Agents"},{"key":"16_CR0016204","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1128\/AAC.00026-09","volume":"53","author":"CS Osborne","year":"2009","unstructured":"Osborne CS, Neckermann G, Fischer E et al (2009) In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. Antimicrob Agents Chemother 53:3777\u20133781","journal-title":"Antimicrob Agents Chemother"},{"key":"16_CR0016205","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.mayocp.2011.12.011","volume":"87","author":"KZ Vardakas","year":"2012","unstructured":"Vardakas KZ, Mavros MN, Roussos N, Falagas ME (2012) Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design. Mayo Clin Proc 87:349\u2013363","journal-title":"Mayo Clin Proc"}],"container-title":["Methods in Molecular Biology","Methicillin-Resistant Staphylococcus Aureus (MRSA) Protocols"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-62703-664-1_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T13:36:17Z","timestamp":1558100177000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-62703-664-1_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,30]]},"ISBN":["9781627036634","9781627036641"],"references-count":205,"URL":"https:\/\/doi.org\/10.1007\/978-1-62703-664-1_16","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-62703-664-1","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,30]]}}}